In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.

Abstract

ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs (in micrograms per milliliter) at which 90% of the isolates tested were inhibited as follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008; and Streptococcus pneumoniae, 0.015. It was four- to sixfold more active than other fluoroquinolones, including against levofloxacin-resistant strains of S. pneumoniae, methicillin-resistant Staphylococcus aureus, and Prevotella species.

• Authors: Ellie J C Goldstein, Diane M Citron, C Vreni Merriam, Yumi A Warren, Kerin L Tyrrell, Helen T Fernandez
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 47 Issue 9 Pg. 3008-11 (Sep 2003) ISSN: 0066-4804 [Print] United States
• PMID: 12937015 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Infective Agents
• Fluoroquinolones
• Quinolones
• delafloxacin

Topics

• Anti-Infective Agents (pharmacology)
• Bacteria, Aerobic (drug effects)
• Bacteria, Anaerobic (drug effects)
• Fluoroquinolones
• Humans
• Microbial Sensitivity Tests
• Paranasal Sinuses (microbiology)
• Quinolones (pharmacology)
• Sinusitis (microbiology)